Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: Technology appraisal guidance [TA540]

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults. Pembrolizumab is not recommended for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin. Pembrolizumab

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours: Technology appraisal guidance [TA539] – NICE

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults. Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive

AlignRT in breast cancer radiotherapy: Medtech innovation briefing [MIB157] – NICE

The technology described in this briefing is the AlignRT patient position monitoring system. This briefing focuses on its use during breast cancer radiation therapy. The innovative aspect is that it may avoid inaccurate treatment by precisely tracking a patient’s position

Dinutuximab beta for treating neuroblastoma: Technology appraisal guidance [TA538] – NICE

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over. Recommendations Dinutuximab beta is recommended as an option for treating high-risk neuroblastoma in people aged 12 months and over whose disease has at least

Screening Quality Assurance Visit Report: NHS Cervical Screening Programme The Royal Free London NHS Foundation Trust – Public Health England

The findings in this report relate to the quality assurance (QA) visit to the Royal Free London NHS Foundation Trust cervical screening service held on 2, 8, 9 and 12 June 2017. The QA visit team identified 14 high priority findings

Screening Quality Assurance Visit Report: NHS cervical screening programme The Rotherham NHS Foundation Trust – Public Health England

The findings in this report relate to the quality-assurance (QA) visit of The Rotherham NHS Foundation Trust screening service held on 25 January 2018. The QA visit team identified 9 high priority findings which related to 3 main themes: governance,

Screening Quality Assurance Visit Report: NHS cervical screening programme Barnsley Hospital NHS Foundation Trust – Public Health England

The findings in this report relate to the quality assurance visit of the Barnsley Hospital NHS Foundation Trust screening service held on 16 November 2017. The QA visit team identified several areas of practice for sharing, including: hospital-based programme co-ordinator focused on

National Bowel Cancer Audit: The feasibility of reporting Patient Reported Outcome Measures as part of a national colorectal cancer audit – Healthcare Quality Improvement Partnership

A feasibility study linking the NHS England National Cancer PROM’s to the National Bowel Cancer Audit (NBOCA) data to establish the feasibility of the PROMs as part of the national clinical audit. This was assessed according to: the characteristics of

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer: Technology appraisal guidance [TA536] – NICE

Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults. Alectinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults.

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine: Technology appraisal guidance [TA535] – NICE

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine. Lenvatinib and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid

Review of the evidence in relation to the treatment criteria for Ibrutinib: Letter from Professor Peter Clark – NHS England

This letter, sent to Professor Stephen Powis, provides information about the re-examination of the commissioning treatment criteria for the use of ibrutinib in previously treated patients with chronic lymphocytic leukaemia (CLL).

Screening Quality Assurance Visit Report: NHS Bowel Cancer Screening Programme West London Bowel Cancer Screening Centre – Public Health England

The findings in this report relate to the quality assurance (QA) visit of West London Bowel Cancer Screening Programme held on 2 November 2017. Finds the West London bowel cancer screening programme is well supported by the director of screening

Screening Quality Assurance visit report: NHS Bowel Cancer Screening Programme Norfolk and Norwich – Public Health England

The findings in this report relate to the quality assurance visit of the Norfolk and Norwich screening service held on 15 November 2017. Finds this well-led and resilient bowel screening team is at the forefront of bowel screening in England. The enthusiastic

National Cancer Patient Experience Survey 2017: National Results Summary – Quality Health

Report that finds for patient experience overall ratings continue to improve, with year on year increases in reported positive experience. Patients also reported more positively on areas including involvement in decisions about care and treatment, and being treated with dignity

Living With and Beyond Cancer – Baseline Activity January – March 2017 – NHS England

This report sets out baseline activity data from January to March 2017 for Stratified Follow Up and Recovery Package interventions. This is the first time national data of this type has been reported.

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer: Technology appraisal guidance [TA531] – NICE

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults. This guidance replaces NICE technology appraisal guidance 447.

Early and locally advanced breast cancer: diagnosis and management: NICE guideline [NG101] – NICE

This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person’s individual preferences. NICE has also produced guidelines on advanced breast cancer, familial breast

Screening Quality Assurance visit report: NHS Breast Screening Programme Lincolnshire – Public Health England

The findings in this report relate to the quality assurance (QA) visit of the Lincolnshire breast screening service held on 19 October 2017. The QA visit team identified 5 high priority findings as summarised below: the breast services review should be concluded

Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable: Technology appraisal guidance [TA492] – NICE

Updated evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults. July 2018: The European Medicines Agency restricted the use of atezolizumab for untreated urothelial carcinoma. It should now only be used in adults with high